BTK and breast cancer: Inhibition of BTK in pre-clinical models of pancreatic cancer, breast cancer and BTK-negative colon cancer have shown only marginal improvement of survival as monotherapy, but when combined with chemo- or immunotherapy, survival was greatly enhanced [231, 242, 243].